| Year |
Citation |
Score |
| 2020 |
Panarelli NC, Hammer STG, Lin J, Gopal P, Nalbantoglu I, Zhao L, Cheng J, Gersten AJ, McHugh JB, Parkash V, Lucas E, Westerhoff M. Reproducibility of AJCC Criteria for Classifying Deeply Invasive Colon Cancers Is Suboptimal for Consistent Cancer Staging. The American Journal of Surgical Pathology. 44: 1381-1388. PMID 32931163 DOI: 10.1097/Pas.0000000000001510 |
0.312 |
|
| 2020 |
Li J, Wang W, Zhang Y, Cieślik M, Guo J, Tan M, Green MD, Wang W, Lin H, Li W, Wei S, Zhou J, Li G, Jing X, Vatan L, ... Zhao L, et al. Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy. The Journal of Clinical Investigation. PMID 32027624 DOI: 10.1172/Jci134402 |
0.308 |
|
| 2019 |
Qin A, Rengan R, Lee S, Santana-Davila R, Goulart BHL, Martins R, Baik C, Kalemkerian GP, Hassan KA, Schneider BJ, Hayman JA, Jolly S, Hearn J, Lawrence TS, Towlerton AMH, ... ... Zhao L, et al. A Pilot Study of Atezolizumab plus Hypofractionated Image-guided Radiotherapy for the Treatment of Advanced Non-Small Cell Lung Cancer. International Journal of Radiation Oncology, Biology, Physics. PMID 31756415 DOI: 10.1016/J.Ijrobp.2019.10.047 |
0.347 |
|
| 2019 |
Zhao L, Koschmann C. Integrating subgroups with mixed-type endpoints in early phase oncology trials. Statistical Methods in Medical Research. 962280219840050. PMID 30945609 DOI: 10.1177/0962280219840050 |
0.308 |
|
| 2019 |
Kim HS, Lu S, Cao Y, Yi Z, Jeyarajan S, Zhao L, Bedi K, Narayanan IV, Paulsen MT, Ljungman M, Shi J. Abstract C28: KMT2D mediates TGF-β-induced epithelial-to-mesenchymal transition to promote more aggressive pancreatic cancer Cancer Research. 79. DOI: 10.1158/1538-7445.Panca19-C28 |
0.343 |
|
| 2018 |
Li W, Tanikawa T, Kryczek I, Xia H, Li G, Wu K, Wei S, Zhao L, Vatan L, Wen B, Shu P, Sun D, Kleer C, Wicha M, Sabel M, et al. Aerobic Glycolysis Controls Myeloid-Derived Suppressor Cells and Tumor Immunity via a Specific CEBPB Isoform in Triple-Negative Breast Cancer. Cell Metabolism. PMID 29805099 DOI: 10.1016/J.Cmet.2018.04.022 |
0.322 |
|
| 2018 |
Zeinali M, Murlidhar V, Fouladdel S, Hafner M, Shao S, Zhao L, Cameron H, Bankhead AI, Shi J, Cuneo KC, Sahai V, Azizi E, Wicha MS, Simeone DM, Nagrath S. Abstract 5579: Increased number of EMT-like CTCs relative to epithelial CTCs reveals signatures of poor outcomes in pancreatic cancer Cancer Research. 78: 5579-5579. DOI: 10.1158/1538-7445.Am2018-5579 |
0.347 |
|
| 2017 |
Harms KL, Chubb H, Zhao L, Fullen DR, Bichakjian CK, Johnson TM, Carskadon S, Palanisamy N, Harms PW. Increased Expression of EZH2 in Merkel Cell Carcinoma Is Associated with Disease Progression and Poorer Prognosis. Human Pathology. PMID 28739498 DOI: 10.1016/J.Humpath.2017.07.009 |
0.306 |
|
| 2017 |
Li H, Zhou W, Li L, Wu J, Liu X, Zhao L, Jia L, Sun Y. Inhibition of Neddylation Modification Sensitizes Pancreatic Cancer Cells to Gemcitabine. Neoplasia (New York, N.Y.). 19: 509-518. PMID 28535453 DOI: 10.1016/J.Neo.2017.04.003 |
0.352 |
|
| 2017 |
Qin A, Street L, Cease K, Viglianti BL, Warren EH, Zhao L, Ramnath N. Clinical Determinants of Durable Clinical Benefit of Pembrolizumab in Veterans With Advanced Non-Small-Cell Lung Cancer. Clinical Lung Cancer. PMID 28366756 DOI: 10.1016/J.Cllc.2017.01.012 |
0.301 |
|
| 2017 |
Fang M, Li Y, Huang K, Qi S, Zhang J, Zgodzinski W, Majewski M, Wallner G, Gozdz S, Macek P, Kowalik A, Pasiarski M, Grywalska E, Vatan L, Nagarsheth N, ... ... Zhao L, et al. IL-33 promotes colon cancer cell stemness via JNK activation and macrophage recruitment. Cancer Research. PMID 28249897 DOI: 10.1158/0008-5472.Can-16-1602 |
0.301 |
|
| 2016 |
Wahl DR, Dresser J, Wilder-Romans K, Parsels JD, Zhao SG, Davis M, Zhao L, Kachman M, Wernisch S, Burant CF, Morgan MA, Feng FY, Speers C, Lyssiotis CA, Lawrence TS. Glioblastoma therapy can be augmented by targeting IDH1-mediated NADPH biosynthesis. Cancer Research. PMID 27923831 DOI: 10.1158/0008-5472.Can-16-2008 |
0.313 |
|
| 2016 |
Davis EJ, Zhao L, Lucas DR, Schuetze SM, Baker LH, Zalupski MM, Thomas D, Chugh R. SPARC expression in patients with high-risk localized soft tissue sarcoma treated on a randomized phase II trial of neo/adjuvant chemotherapy. Bmc Cancer. 16: 663. PMID 27544129 DOI: 10.1186/S12885-016-2694-2 |
0.301 |
|
| 2016 |
Peng D, Tanikawa T, Li W, Zhao L, Vatan L, Szeliga W, Wan S, Wei S, Wang Y, Liu Y, Staroslawska E, Szubstarski F, Rolinski J, Grywalska E, Stanislawek A, et al. Myeloid-derived suppressor cells endow stem-like qualities to breast cancer cells through IL-6/STAT3 and NO/NOTCH cross-talk signaling. Cancer Research. PMID 27197152 DOI: 10.1158/0008-5472.Can-15-2528 |
0.318 |
|
| 2016 |
Wang W, Kryczek I, Dostál L, Lin H, Tan L, Zhao L, Lu F, Wei S, Maj T, Peng D, He G, Vatan L, Szeliga W, Kuick R, Kotarski J, et al. Effector T Cells Abrogate Stroma-Mediated Chemoresistance in Ovarian Cancer. Cell. PMID 27133165 DOI: 10.1016/J.Cell.2016.04.009 |
0.301 |
|
| 2016 |
Shi J, Silverman B, Zhao L. Abstract B26: Altered eIF3f subcellular localization and expression in pancreatic ductal adenocarcinomas and its precursor lesions Cancer Research. 76. DOI: 10.1158/1538-7445.Panca16-B26 |
0.304 |
|
| 2015 |
Kausar T, Schreiber JS, Karnak D, Parsels LA, Parsels JD, Davis MA, Zhao L, Maybaum J, Lawrence TS, Morgan MA. Sensitization of Pancreatic Cancers to Gemcitabine Chemoradiation by WEE1 Kinase Inhibition Depends on Homologous Recombination Repair. Neoplasia (New York, N.Y.). 17: 757-66. PMID 26585231 DOI: 10.1016/J.Neo.2015.09.006 |
0.323 |
|
| 2015 |
Nagarsheth N, Peng D, Kryczek I, Wu K, Li W, Zhao E, Zhao L, Wei S, Frankel T, Vatan L, Szeliga W, Dou Y, Owens S, Marquez V, Tao K, et al. PRC2 epigenetically silences Th1-type chemokines to suppress effector T cell trafficking in colon cancer. Cancer Research. PMID 26567139 DOI: 10.1158/0008-5472.Can-15-1938 |
0.328 |
|
| 2015 |
Zhao E, Maj T, Kryczek I, Li W, Wu K, Zhao L, Wei S, Crespo J, Wan S, Vatan L, Szeliga W, Shao I, Wang Y, Liu Y, Varambally S, et al. Cancer mediates effector T cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction. Nature Immunology. PMID 26523864 DOI: 10.1038/Ni.3313 |
0.309 |
|
| 2015 |
Swiecicki PL, Zhao L, Belile E, Sacco AG, Chepeha DB, Dobrosotskaya I, Spector M, Shuman A, Malloy K, Moyer J, McKean E, McLean S, Wolf GT, Eisbruch A, Prince M, et al. A phase II study evaluating axitinib in patients with unresectable, recurrent or metastatic head and neck cancer. Investigational New Drugs. PMID 26453566 DOI: 10.1007/S10637-015-0293-8 |
0.304 |
|
| 2015 |
Kryczek I, Cui TX, Zhao L, Vatan L, Szeliga W, Liu R, Zou W. Abstract POSTER-BIOL-1332: Molecular, cellular and clinical interaction between MDSC and ovarian cancer stemness Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Ovcasymp14-Poster-Biol-1332 |
0.335 |
|
| 2015 |
Murlidhar V, Reddy RM, Azizi E, Zhao L, Grabauskiene S, Zhang Z, Ramnath N, Lin J, Chang AC, Carrott PW, Lynch WR, Orringer MB, Wicha MS, Palanisamy N, Beer DG, et al. Abstract 1581: A study of pulmonary and peripheral vein blood as sources of circulating tumor cells in early lung cancer Cancer Research. 75: 1581-1581. DOI: 10.1158/1538-7445.Am2015-1581 |
0.331 |
|
| 2014 |
Karnak D, Engelke CG, Parsels LA, Kausar T, Wei D, Robertson JR, Marsh KB, Davis MA, Zhao L, Maybaum J, Lawrence TS, Morgan MA. Combined inhibition of Wee1 and PARP1/2 for radiosensitization in pancreatic cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 5085-96. PMID 25117293 DOI: 10.1158/1078-0432.Ccr-14-1038 |
0.333 |
|
| 2014 |
Kryczek I, Lin Y, Nagarsheth N, Peng D, Zhao L, Zhao E, Vatan L, Szeliga W, Dou Y, Owens S, Zgodzinski W, Majewski M, Wallner G, Fang J, Huang E, et al. IL-22(+)CD4(+) T cells promote colorectal cancer stemness via STAT3 transcription factor activation and induction of the methyltransferase DOT1L. Immunity. 40: 772-84. PMID 24816405 DOI: 10.1016/J.Immuni.2014.03.010 |
0.309 |
|
| 2014 |
Sacco AG, Zhao L, Carey TE, Dobrosotskaya IY, McHugh JB, Chepeha DB, Bradford CR, Wolf GT, Prince ME, Moyer J, McKean EL, McLean SA, Malloy KM, Spector ME, Hogikyan ND, et al. Phase II trial evaluating axitinib for patients with unresectable, recurrent, or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Journal of Clinical Oncology. 32. DOI: 10.1200/Jco.2014.32.15_Suppl.E17027 |
0.303 |
|
| 2013 |
Cui TX, Kryczek I, Zhao L, Zhao E, Kuick R, Roh MH, Vatan L, Szeliga W, Mao Y, Thomas DG, Kotarski J, Tarkowski R, Wicha M, Cho K, Giordano T, et al. Myeloid-derived suppressor cells enhance stemness of cancer cells by inducing microRNA101 and suppressing the corepressor CtBP2. Immunity. 39: 611-21. PMID 24012420 DOI: 10.1016/J.Immuni.2013.08.025 |
0.323 |
|
| 2013 |
Engelke CG, Parsels LA, Qian Y, Zhang Q, Karnak D, Robertson JR, Tanska DM, Wei D, Davis MA, Parsels JD, Zhao L, Greenson JK, Lawrence TS, Maybaum J, Morgan MA. Sensitization of pancreatic cancer to chemoradiation by the Chk1 inhibitor MK8776. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 4412-21. PMID 23804422 DOI: 10.1158/1078-0432.Ccr-12-3748 |
0.328 |
|
| 2013 |
Wei D, Parsels LA, Karnak D, Davis MA, Parsels JD, Marsh AC, Zhao L, Maybaum J, Lawrence TS, Sun Y, Morgan MA. Inhibition of protein phosphatase 2A radiosensitizes pancreatic cancers by modulating CDC25C/CDK1 and homologous recombination repair. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 4422-32. PMID 23780887 DOI: 10.1158/1078-0432.Ccr-13-0788 |
0.332 |
|
| 2013 |
Sheetz KH, Zhao L, Holcombe SA, Wang SC, Reddy RM, Lin J, Orringer MB, Chang AC. Decreased core muscle size is associated with worse patient survival following esophagectomy for cancer Diseases of the Esophagus. 26: 716-722. PMID 23350746 DOI: 10.1111/Dote.12020 |
0.302 |
|
| 2013 |
Wei D, Parsels LA, Davis MA, Zhao L, Maybaum J, Lawrence TS, Sun Y, Morgan MA. Abstract 1582: Inhibition of protein phosphatase 2A radiosensitizes pancreatic cancer cells by modulation of CDC25C. Cancer Research. 73: 1582-1582. DOI: 10.1158/1538-7445.Am2013-1582 |
0.347 |
|
| 2012 |
Venkatesha VA, Parsels LA, Parsels JD, Zhao L, Zabludoff SD, Simeone DM, Maybaum J, Lawrence TS, Morgan MA. Sensitization of pancreatic cancer stem cells to gemcitabine by Chk1 inhibition. Neoplasia (New York, N.Y.). 14: 519-25. PMID 22787433 DOI: 10.1593/Neo.12538 |
0.328 |
|
| 2012 |
Schuetze SM, Zhao L, Chugh R, Thomas DG, Lucas DR, Metko G, Zalupski MM, Baker LH. Results of a phase II study of sirolimus and cyclophosphamide in patients with advanced sarcoma. European Journal of Cancer (Oxford, England : 1990). 48: 1347-53. PMID 22525224 DOI: 10.1016/J.Ejca.2012.03.022 |
0.306 |
|
| 2012 |
Wei D, Li H, Yu J, Sebolt JT, Zhao L, Lawrence TS, Smith PG, Morgan MA, Sun Y. Radiosensitization of human pancreatic cancer cells by MLN4924, an investigational NEDD8-activating enzyme inhibitor. Cancer Research. 72: 282-93. PMID 22072567 DOI: 10.1158/0008-5472.Can-11-2866 |
0.334 |
|
| 2012 |
Akateh C, Zhao L, Orringer MB, Chang AC, Lin J, Reddy RM. Abstract 2662: Racial disparities in the surgical outcomes after esophagectomy for esophageal cancer Cancer Research. 72: 2662-2662. DOI: 10.1158/1538-7445.Am2012-2662 |
0.301 |
|
| 2011 |
Vance S, Liu E, Zhao L, Parsels JD, Parsels LA, Brown JL, Maybaum J, Lawrence TS, Morgan MA. Selective radiosensitization of p53 mutant pancreatic cancer cells by combined inhibition of Chk1 and PARP1. Cell Cycle (Georgetown, Tex.). 10: 4321-9. PMID 22134241 DOI: 10.4161/Cc.10.24.18661 |
0.316 |
|
| 2011 |
Ray D, Ahsan A, Helman A, Chen G, Hegde A, Gurjar SR, Zhao L, Kiyokawa H, Beer DG, Lawrence TS, Nyati MK. Regulation of EGFR protein stability by the HECT-type ubiquitin ligase SMURF2. Neoplasia (New York, N.Y.). 13: 570-8. PMID 21750651 DOI: 10.1593/Neo.11632 |
0.324 |
|
| 2011 |
Parsels LA, Qian Y, Tanska DM, Gross M, Zhao L, Hassan MC, Arumugarajah S, Parsels JD, Hylander-Gans L, Simeone DM, Morosini D, Brown JL, Zabludoff SD, Maybaum J, Lawrence TS, et al. Assessment of chk1 phosphorylation as a pharmacodynamic biomarker of chk1 inhibition. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 3706-15. PMID 21482692 DOI: 10.1158/1078-0432.Ccr-10-3082 |
0.345 |
|
| 2011 |
Chen G, Kim SH, King AN, Zhao L, Simpson RU, Christensen PJ, Wang Z, Thomas DG, Giordano TJ, Lin L, Brenner DE, Beer DG, Ramnath N. CYP24A1 is an independent prognostic marker of survival in patients with lung adenocarcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 817-26. PMID 21169243 DOI: 10.1158/1078-0432.Ccr-10-1789 |
0.306 |
|
| 2010 |
Morgan MA, Parsels L, Zhao L, Parsels J, Davis M, Arumugarajah S, Canman C, Zabludoff S, Maybaum J, Lawrence T. Abstract 491: The roles of homologous recombination repair and cell cycle checkpoints in radiosensitization by the Chk1/2 inhibitor, AZD7762 Cancer Research. 70: 491-491. DOI: 10.1158/1538-7445.Am10-491 |
0.311 |
|
| 2010 |
Parsels LA, Morgan MA, Tanska DM, Parsels JD, Davis MA, Hassan MC, Arumugarajah S, Hylander-Gans L, Morosini D, Zhao L, Simeone DM, Canman CE, Normolle DP, Zabludoff SD, Lawrence TS, et al. Abstract 1765: Preclinical optimization of the Chk1/2 inhibitor AZD7762 in combination with gemcitabine in pancreatic cancer Cancer Research. 70: 1765-1765. DOI: 10.1158/1538-7445.Am10-1765 |
0.354 |
|
| 2009 |
Zhao L, Woodworth G. Bayesian decision sequential analysis with survival endpoint in phase II clinical trials Statistics in Medicine. 28: 1339-1352. PMID 19226557 DOI: 10.1002/Sim.3544 |
0.509 |
|
| 2008 |
Wang L, Piert M, Zhao L, Lawrence T, Kong F. PET Study Demonstrates Radiation Dependent Changes on Tumor Hypoxia and Proliferation during the Course of Radiotherapy in a Lung Cancer Xenograft Model International Journal of Radiation Oncology Biology Physics. 72. DOI: 10.1016/J.Ijrobp.2008.06.833 |
0.313 |
|
| 2008 |
Correa CR, Wang L, Zhao L, Hayman J, Kalemkerian G, Cease K, Brenner D, Kong FM. The Influence of Cardiac and Pulmonary Comorbidities on Overall Survival (OS) among Stage III Non-small Cell Lung Cancer (NSCLC) Patients Treated with Definitive Radiotherapy (RT) International Journal of Radiation Oncology Biology Physics. 72. DOI: 10.1016/J.Ijrobp.2008.06.1349 |
0.312 |
|
| 2007 |
Wang L, Zhao L, Hayman J, Kalemkerian G, Kong F. Radiation dose is significantly associated with overall survival in patients with stage III non-small cell lung cancer treated with combined radiation and chemotherapy Journal of Clinical Oncology. 25: 18074-18074. DOI: 10.1200/Jco.2007.25.18_Suppl.18074 |
0.316 |
|
| 2007 |
Wang L, Zhao L, Correa C, Hayman J, Kalemkerian G, Lyons S, Cease K, Brenner D, Kong F. Radiation Dose is an Independent Predictor for Overall Survival in Patients With Stage III Unresectable Non-small Cell Lung Cancer Treated by Radiation With and Without Chemotherapy International Journal of Radiation Oncology Biology Physics. 69. DOI: 10.1016/J.Ijrobp.2007.07.108 |
0.313 |
|
| 2006 |
Chapet O, Haken RKT, Quint L, Zhao L, Martel MK, Hayman JA, Kong F. 2476 : Incidental Irradiation to Non-Involved Nodal stations in Patients With Stage III Non-Small Cell Lung Cancer Treated With 3-D Conformal Radiation Therapy International Journal of Radiation Oncology Biology Physics. 66. DOI: 10.1016/J.Ijrobp.2006.07.887 |
0.307 |
|
| 2006 |
Zhao L, West B, Hayman J, Kalemkerian G, Lyons S, Cease K, Kong F. 161 : High Radiation Dose May Overcome the Negative Effect of Large Gross Tumor Volume in Patients With Early Stage Non-Small-Cell Lung Cancer International Journal of Radiation Oncology Biology Physics. 66. DOI: 10.1016/J.Ijrobp.2006.07.193 |
0.323 |
|
| Show low-probability matches. |